SILVER SPRING, Md. — Aurobindo Pharma on Thursday announced that the Food and Drug Administration had approved its generic of AstraZeneca’s Prilosec (omeprazole) delayed-release capsules. The drug is intended to treat gastroesophogeal reflux disease, short-term treatment duodenal and gastric ulcers and the maintenance of healing erosive esophagitis.

The drug will be available in 10-, 20- and 40-mg delayed-release capsules. The branded product saw U.S. sales of $422.8 million in the 12 months ended July 2015, according to IMS Health.